In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist 1 The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health 1 In addition to these positive results, Boehringer is advancing its broad metabolic health R&D program, exploring multiple pharmaceutical approaches to weight management including oral treatments Ingelheim, Germany
Older adults or those engaging in regular resistance training may benefit from higher protein intake (1.2-1.5 g/kg/day)
10.1002/oby.23673
doi: 10.1016/j.ultsonch.2023.106742 38 Vilchis-GmezDSCaldern-SantoyoMBarros-CastilloJCZamora-GasgaVMRagazzo-SnchezJA
Individuals with a History of Gastrointestinal Issues GLP-1 medications are known for causing nausea, vomiting, diarrhea, and constipationespecially during dose escalation
Hm lng Vitamin C cao hn lm tng tc dng lm sng ca glutathione, to ra ln da sng hn, sn chc hn
